在非小细胞肺癌（NSCLC）中，STK11 突变与免疫抑制性肿瘤微环境（ITEM）、抗 PD-1（αPD1）治疗失败相关。研究人员制备仿生基因递送系统 STK11@PPCM，发现其能逆转 ITEM、增强 αPD1 疗效，为 STK11 突变肺腺癌治疗提供新策略。 肺癌，这个 “癌症杀手”，多年来一直稳 ...

Analysis of genetic mutations and cellular signaling pathways revealed that driver mutations of genes known to be associated with cancer, such as STK11 and ERBB2, were observed in the tissues of ...